Protein Therapeutics Market

Protein Therapeutics Market (Product: Monoclonal Antibodies, Enzyme Replacement Therapy, Cytokines, Fusion Proteins, Anti-coagulants, Bone Morphogenetic Proteins (BMPs), Hormones, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031

Global Protein Therapeutics Market Outlook 2031

  • The industry was valued at US$ 318.4 Bn in 2022
  • It is projected to grow at a CAGR of 6.3% from 2023 to 2031 and reach more than US$ 549.4 Bn by the end of 2031

Analyst Viewpoint

Increase in incidence of chronic diseases such as cancer, diabetes, and autoimmune disorders is driving the global market. Proteins play a crucial role in various biological processes, and leveraging their therapeutic potential has paved the way for innovative treatments for a wide range of diseases. Advancements in biotechnology and genetic engineering enabling large-scale production of therapeutic proteins and addressing the challenges associated with sourcing proteins from natural origins is another factor propelling market expansion. Furthermore, growth of the biosimilars market is likely to fuel the global protein therapeutics market size during the forecast period.

Advancements in protein engineering and formulation techniques offer lucrative opportunities to protein therapeutics market players. Companies are focusing on developing personalized medicine, with emphasis on targeted therapies tailored to individual patients based on their genetic makeup and disease characteristics.

Protein Therapeutics Market

Global Protein Therapeutics Market Overview

Protein therapeutics refer to the use of proteins as therapeutic agents to treat various medical conditions and diseases. Unlike traditional small-molecule drugs, protein therapeutics are larger, more complex molecules that often mimic or interfere with natural proteins in the body to modify or regulate biological processes. These therapeutic proteins can be naturally occurring or engineered through biotechnological methods.

Increase in Incidence of Chronic Diseases Driving Market Progress

Rise in incidence of chronic conditions, including cancer, diabetes, and autoimmune disorders, is propelling demand for innovative therapeutic approaches with proteins, particularly monoclonal antibodies that are playing a pivotal role in addressing these complex medical challenges.

Cancer, a leading cause of morbidity and mortality globally, has witnessed a steady rise in new cases each year. Similarly, the escalating rates of diabetes, both type 1 and type 2, contribute to a substantial burden on healthcare systems.

Proteins, especially monoclonal antibodies, have emerged as crucial agents in the treatment of these chronic conditions. Monoclonal antibodies, designed to mimic the immune system's ability to fight off harmful pathogens, are engineered to target specific proteins involved in disease processes. In cancer treatment, monoclonal antibodies can selectively bind to cancer cells, modulating the immune response and inhibiting tumor growth.

Ongoing research and development efforts continue to refine protein therapeutics, expanding their applications and improving treatment outcomes. Development of next-generation monoclonal antibodies, bispecific antibodies, and other protein-based modalities showcases the commitment to innovation. Thus, surge in incidence of chronic diseases is fueling the global protein therapeutics market growth.

Growth of Biosimilars Market Propelling Demand for Protein Therapeutics

Expiration of patents for key biologics is fueling the biosimilars market. This has provided manufacturers opportunities to develop more affordable alternatives, fostering competition and increasing accessibility to critical biologic therapies. Expiration of patents for established biologics marks the entry of biosimilars into the market.

Biosimilars are biological products that are highly similar to, and have no clinically meaningful differences from, an existing approved reference biologic. The expiration of patents allows other manufacturers to develop and market biosimilars, introducing competition to the market for specific biologic therapies.

Potential for cost savings is a primary catalyst for the rise of biosimilars. Biologics, which are complex and often high-cost therapeutic proteins, contribute significantly to healthcare expenditure. As patents expire and biosimilars enter the market, they are generally priced lower than the originator biologics. This competitive pricing creates opportunities for healthcare systems, providers, and patients to access these vital treatments at reduced costs.

Manufacturers of biosimilars benefit from a streamlined regulatory pathway, designed to ensure the safety, efficacy, and quality of these products. The regulatory framework for biosimilars aims to strike a balance between incentivizing innovation and promoting competition, encouraging manufacturers to invest in the development of biosimilars.

Introduction of biosimilars also plays a role in increasing market competition and improving overall healthcare system sustainability. With multiple manufacturers producing biosimilars for a given biologic, market forces drive prices down, providing cost-effective alternatives for patients and healthcare providers.

Pivotal Role in Treating Various Diseases Propelling Demand for Monoclonal Antibodies

In terms of product, the monoclonal antibodies segment accounted for the largest global protein therapeutics market share in 2022. This is ascribed to the pivotal role played by monoclonal antibodies in treating various diseases.

Engineered to mimic the immune system's ability to target specific cells, mAbs are extensively utilized for their precision in binding to disease-related antigens. Ongoing research, technological advancements, and approval of novel therapies are bolstering the monoclonal antibodies segment. With their high specificity and therapeutic potential, monoclonal antibodies are a cornerstone in the rapidly expanding landscape of protein therapeutics.

Targeting of Cancer Cells Driving Demand for Monoclonal Antibodies

Based on application, the cancer segment dominated the global protein therapeutics market in 2022. The trend is expected to continue during the forecast period.

Monoclonal antibodies, particularly immune checkpoint inhibitors and antibody-drug conjugates, have revolutionized cancer treatment by specifically targeting cancer cells while minimizing damage to healthy tissues. These protein therapeutics have demonstrated remarkable success in various cancer types, significantly improving patient outcomes and survival rates.

Regional Outlook

According to protein therapeutics market analysis, North America is expected to witness robust growth in the next few years. This is ascribed to technological advancements, increase in prevalence of chronic diseases, and well-established biopharmaceutical sector.

The region boasts a strong biopharmaceutical industry, particularly in the U.S. Presence of major pharmaceutical companies, research institutions, and skilled workforce fosters innovation and accelerates the development of protein therapeutics. The U.S. FDA's proactive regulatory approach toward biologics and protein-based drugs further supports the rapid entry of novel therapies into the protein therapeutics market.

As per protein therapeutics market research, Asia Pacific witnessed robust growth in 2022. Increase in healthcare infrastructure, large & diverse patient population, rise in prevalence of chronic diseases, and growing emphasis on biopharmaceutical research and development are propelling the market in the region.

The region's healthcare landscape is evolving rapidly, with countries such as China, India, Japan, and South Korea investing significantly in healthcare infrastructure. This growth enhances the accessibility of protein therapeutics, contributing to increased patient demand.

Analysis of Key Players

The global protein therapeutics market is fragmented, with the presence of large number of players. Companies are focusing on investment in R&D and collaborations to increase market share.

Thermo Fisher Scientific, Inc., Genzyme Corporation (Sanofi), AbbVie, Inc., Sanofi, Leadiant Biosciences, Takeda Pharmaceutical Company Limited, Amicus Therapeutics, Bayer AG, Bristol-Myers Squibb, Daiichi Sankyo Company, Abbott, and Sanofi are the prominent players in the protein therapeutics market.

Key Developments in Global Protein Therapeutics Industry

  • In January 2022, Thermo Fisher Scientific, Inc. completed the acquisition of PeproTech, a leading provider of recombinant proteins, for a total cash purchase price of US$ 1.85 Bn. PeproTech, based in Cranbury, New Jersey, is a privately held provider of bioscience reagents, including cytokines and growth factors, used in the development and manufacturing of cell and gene therapies and broader cell culture applications. The acquisition will enable Thermo Fisher to provide customers significant benefits through an integrated offering.
  • In April 2022, Plexium and AbbVie partnered to develop and commercialize targeted protein degradation (TPD) therapeutics for neurological conditions. The collaboration combines AbbVie's neuroscience expertise with Plexium's comprehensive TPD platform, which enables the discovery of novel therapies toward historically challenging drug targets. The partnership aims to strengthen Plexium's leadership position in TPD and broaden its best-in-class capabilities into neurological diseases. The collaboration will involve preclinical research activities for collaboration targets, with AbbVie selecting programs for additional research and development.

Key players have been profiled in the protein therapeutics market report based on parameters such as company overview, latest developments, business strategies, application portfolio, business segments, and financial overview.

Global Protein Therapeutics Market Snapshot

Attribute Detail
Size in 2022 US$ 318.4 Bn
Forecast (Value) in 2031 More than US$ 549.4 Bn
Growth Rate (CAGR) 6.3%
Forecast Period 2023-2031
Historical Data Available for 2017-2021
Quantitative Units US$ Bn for Value
Market Analysis It includes segment analysis as well as regional level analysis. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, Porter’s Five Forces analysis, value chain analysis, and key trend analysis.
Competition Landscape
  • Market share analysis by company (2021)
  • Company profiles section includes overview, product portfolio, sales footprint, key subsidiaries or distributors, strategy & recent developments, and key financials
Format Electronic (PDF) + Excel
Market Segmentation
  • Product
    • Monoclonal Antibodies
    • Enzyme Replacement Therapy
    • Cytokines
      • Interferons
      • Interleukins
      • Growth Factors
    • Fusion Proteins
    • Anti-coagulants
    • Bone Morphogenetic Proteins (BMPs)
    • Hormones
    • Others (engineered protein scaffolds, etc.)
  • Application
    • Metabolic Disorders
    • Immunologic Disorders
    • Hematological Disorders
    • Cancer
    • Genetic Disorders
  • Route of Administration
    • Injectable Proteins
    • Oral Proteins
Regions Covered
  • North America
  • Europe
  • Asia Pacific
  • Latina America
Countries Covered
  • U.S.
  • Canada
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • China
  • India
  • Japan
  • Australia & New Zealand
  • Brazil
  • Mexico
  • GCC Countries
  • South Africa
Companies Profiled
  • Thermo Fisher Scientific, Inc.
  • Genzyme Corporation (Sanofi)
  • AbbVie, Inc.
  • Sanofi
  • Leadiant Biosciences
  • Takeda Pharmaceutical Company Limited
  • Amicus Therapeutics
  • Bayer AG
  • Bristol-Myers Squibb
  • Daiichi Sankyo Company
  • Abbott
  • Sanofi
Customization Scope Available upon request
Pricing Available upon request

Frequently Asked Questions

How big was the global protein therapeutics market in 2022?

It was valued at US$ 318.4 Bn in 2022.

How big will the protein therapeutics business be by 2031?

It is projected to reach more than US$ 549.4 Bn by 2031.

What will be the CAGR of the protein therapeutics industry during the forecast period?

The CAGR is anticipated be 6.3% from 2023 to 2031.

Which are the prominent trends driving demand for protein therapeutics?

Increase in incidence of chronic diseases, advancements in biotechnology, and growth of biosimilars market

What was the share of the leading protein therapeutics segment in 2022?

The monoclonal antibodies product segment accounted for more than 49% share in 2022.

Which region will account for major share of the protein therapeutics sector during the forecast period?

North America is expected to account for the largest share from 2023 to 2031.

Who are the prominent manufacturers of protein therapeutics?

Thermo Fisher Scientific, Inc., Genzyme Corporation (Sanofi), AbbVie, Inc., Sanofi, Leadiant Biosciences, Takeda Pharmaceutical Company Limited, Amicus Therapeutics, Bayer AG, Bristol-Myers Squibb, Daiichi Sankyo Company, Abbott, and Sanofi.

    1. Preface

        1.1. Market Definition and Scope

        1.2. Market Segmentation

        1.3. Key Research Objectives

        1.4. Research Highlights

    2. Assumptions and Research Methodology

    3. Executive Summary: Global Protein Therapeutics Market

    4. Market Overview

        4.1. Introduction

            4.1.1. Product Definition

            4.1.2. Industry Evolution / Developments

        4.2. Overview

        4.3. Market Dynamics

            4.3.1. Drivers

            4.3.2. Restraints

            4.3.3. Opportunities

        4.4. Global Protein Therapeutics Market Analysis and Forecast, 2017–2031

            4.4.1. Market Revenue Projections (US$ Mn)

            4.4.2. Market Volume/Unit Shipments Projections

        4.5. Porter’s Five Force Analysis

    5. Key Insights

        5.1. Therapeutic monoclonal antibodies approved or in review in the EU or US.

        5.2. Regulatory Scenario

        5.3. Key Products or Brand Analysis

        5.4. Technological Advances in Protein Therapeutics.

        5.5. Engineering protein-based therapeutics through structural and chemical design

    6. Global Protein Therapeutics Market Analysis and Forecast, By Product

        6.1. Introduction & Definition

        6.2. Key Findings / Developments

        6.3. Market Value Forecast, by Product, 2017–2031

            6.3.1. Monoclonal Antibodies

            6.3.2. Enzyme Replacement Therapy

            6.3.3. Cytokines

                6.3.3.1. Interferons

                6.3.3.2. Interleukins

                6.3.3.3. Growth Factors

            6.3.4. Fusion Proteins

            6.3.5. Anti-coagulants

            6.3.6. Bone Morphogenetic Proteins (BMPs)

            6.3.7. Hormones

            6.3.8. Others (engineered protein scaffolds, etc.)

        6.4. Market Attractiveness Analysis, By Product

    7. Global Protein Therapeutics Market Analysis and Forecast, By Application

        7.1. Introduction & Definition

        7.2. Key Findings / Developments

        7.3. Market Value Forecast, by Application, 2017–2031

            7.3.1. Metabolic Disorders

            7.3.2. Immunologic Disorders

            7.3.3. Hematological Disorders

            7.3.4. Cancer

            7.3.5. Genetic Disorders

        7.4. Market Attractiveness Analysis, By Application

    8. Global Protein Therapeutics Market Analysis and Forecast, By Route of Administration

        8.1. Introduction & Definition

        8.2. Key Findings / Developments

        8.3. Market Value Forecast, by Route of Administration, 2017–2031

            8.3.1. Injectable Proteins

            8.3.2. Oral Proteins

        8.4. Market Attractiveness Analysis, By Route of Administration

    9. Global Protein Therapeutics Market Analysis and Forecast, By Region

        9.1. Key Findings

        9.2. Market Value Forecast, by Region

            9.2.1. North America

            9.2.2. Europe

            9.2.3. Asia Pacific

            9.2.4. Latin America

            9.2.5. Middle East & Africa

        9.3. Market Attractiveness Analysis, By Region

    10. North America Protein Therapeutics Market Analysis and Forecast

        10.1. Introduction

            10.1.1. Key Findings

        10.2. Market Value Forecast, by Product, 2017–2031

            10.2.1. Monoclonal Antibodies

            10.2.2. Enzyme Replacement Therapy

            10.2.3. Cytokines

                10.2.3.1. Interferons

                10.2.3.2. Interleukins

                10.2.3.3. Growth Factors

            10.2.4. Fusion Proteins

            10.2.5. Anti-coagulants

            10.2.6. Bone Morphogenetic Proteins (BMPs)

            10.2.7. Hormones

            10.2.8. Others (engineered protein scaffolds, etc.)

        10.3. Market Value Forecast, by Application, 2017–2031

            10.3.1. Metabolic Disorders

            10.3.2. Immunologic Disorders

            10.3.3. Hematological Disorders

            10.3.4. Cancer

            10.3.5. Genetic Disorders

        10.4. Market Value Forecast, by Route of Administration, 2017–2031

            10.4.1. Injectable Proteins

            10.4.2. Oral Proteins

        10.5. Market Value Forecast, by Country, 2017–2031

            10.5.1. U.S.

            10.5.2. Canada

        10.6. Market Attractiveness Analysis

            10.6.1. By Product

            10.6.2. By Application

            10.6.3. By Route of Administration

            10.6.4. By Country

    11. Europe Protein Therapeutics Market Analysis and Forecast

        11.1. Introduction

            11.1.1. Key Findings

        11.2. Market Value Forecast, by Product, 2017–2031

            11.2.1. Monoclonal Antibodies

            11.2.2. Enzyme Replacement Therapy

            11.2.3. Cytokines

                11.2.3.1. Interferons

                11.2.3.2. Interleukins

                11.2.3.3. Growth Factors

            11.2.4. Fusion Proteins

            11.2.5. Anti-coagulants

            11.2.6. Bone Morphogenetic Proteins (BMPs)

            11.2.7. Hormones

            11.2.8. Others (engineered protein scaffolds, etc.)

        11.3. Market Value Forecast, by Application, 2017–2031

            11.3.1. Metabolic Disorders

            11.3.2. Immunologic Disorders

            11.3.3. Hematological Disorders

            11.3.4. Cancer

            11.3.5. Genetic Disorders

        11.4. Market Value Forecast, by Route of Administration, 2017–2031

            11.4.1. Injectable Proteins

            11.4.2. Oral Proteins

        11.5. Market Value Forecast, by Country/Sub-region, 2017–2031

            11.5.1. Germany

            11.5.2. U.K.

            11.5.3. France

            11.5.4. Italy

            11.5.5. Spain

            11.5.6. Rest of Europe

        11.6. Market Attractiveness Analysis

            11.6.1. By Product

            11.6.2. By Application

            11.6.3. By Route of Administration

            11.6.4. By Country/Sub-region

    12. Asia Pacific Protein Therapeutics Market Analysis and Forecast

        12.1. Introduction

            12.1.1. Key Findings

        12.2. Market Value Forecast, by Product, 2017–2031

            12.2.1. Monoclonal Antibodies

            12.2.2. Enzyme Replacement Therapy

            12.2.3. Cytokines

                12.2.3.1. Interferons

                12.2.3.2. Interleukins

                12.2.3.3. Growth Factors

            12.2.4. Fusion Proteins

            12.2.5. Anti-coagulants

            12.2.6. Bone Morphogenetic Proteins (BMPs)

            12.2.7. Hormones

            12.2.8. Others (engineered protein scaffolds, etc.)

        12.3. Market Value Forecast, by Application, 2017–2031

            12.3.1. Metabolic Disorders

            12.3.2. Immunologic Disorders

            12.3.3. Hematological Disorders

            12.3.4. Cancer

            12.3.5. Genetic Disorders

        12.4. Market Value Forecast, by Route of Administration, 2017–2031

            12.4.1. Injectable Proteins

            12.4.2. Oral Proteins

        12.5. Market Value Forecast, by Country/Sub-region, 2017–2031

            12.5.1. China

            12.5.2. India

            12.5.3. Japan

            12.5.4. Australia & New Zealand

            12.5.5. Rest of Asia Pacific

        12.6. Market Attractiveness Analysis

            12.6.1. By Product

            12.6.2. By Application

            12.6.3. By Route of Administration

            12.6.4. By Country/Sub-region

    13. Latin America Protein Therapeutics Market Analysis and Forecast

        13.1. Introduction

            13.1.1. Key Findings

        13.2. Market Value Forecast, by Product, 2017–2031

            13.2.1. Monoclonal Antibodies

            13.2.2. Enzyme Replacement Therapy

            13.2.3. Cytokines

                13.2.3.1. Interferons

                13.2.3.2. Interleukins

                13.2.3.3. Growth Factors

            13.2.4. Fusion Proteins

            13.2.5. Anti-coagulants

            13.2.6. Bone Morphogenetic Proteins (BMPs)

            13.2.7. Hormones

            13.2.8. Others (engineered protein scaffolds, etc.)

        13.3. Market Value Forecast, by Application, 2017–2031

            13.3.1. Metabolic Disorders

            13.3.2. Immunologic Disorders

            13.3.3. Hematological Disorders

            13.3.4. Cancer

            13.3.5. Genetic Disorders

        13.4. Market Value Forecast, by Route of Administration, 2017–2031

            13.4.1. Injectable Proteins

            13.4.2. Oral Proteins

        13.5. Market Value Forecast, by Country/Sub-region, 2017–2031

            13.5.1. Brazil

            13.5.2. Mexico

            13.5.3. Rest of Latin America

        13.6. Market Attractiveness Analysis

            13.6.1. By Product

            13.6.2. By Application

            13.6.3. By Route of Administration

            13.6.4. By Country/Sub-region

    14. Middle East & Africa Protein Therapeutics Market Analysis and Forecast

        14.1. Introduction

            14.1.1. Key Findings

        14.2. Market Value Forecast, by Product, 2017–2031

            14.2.1. Monoclonal Antibodies

            14.2.2. Enzyme Replacement Therapy

            14.2.3. Cytokines

                14.2.3.1. Interferons

                14.2.3.2. Interleukins

                14.2.3.3. Growth Factors

            14.2.4. Fusion Proteins

            14.2.5. Anti-coagulants

            14.2.6. Bone Morphogenetic Proteins (BMPs)

            14.2.7. Hormones

            14.2.8. Others (engineered protein scaffolds, etc.)

        14.3. Market Value Forecast, by Application, 2017–2031

            14.3.1. Metabolic Disorders

            14.3.2. Immunologic Disorders

            14.3.3. Hematological Disorders

            14.3.4. Cancer

            14.3.5. Genetic Disorders

        14.4. Market Value Forecast, by Route of Administration, 2017–2031

            14.4.1. Injectable Proteins

            14.4.2. Oral Proteins

        14.5. Market Value Forecast, by Country/Sub-region, 2017–2031

            14.5.1. GCC Countries

            14.5.2. South Africa

            14.5.3. Rest of Middle East & Africa

        14.6. Market Attractiveness Analysis

            14.6.1. By Product

            14.6.2. By Application

            14.6.3. By Route of Administration

            14.6.4. By Country/Sub-region

    15. Competition Landscape

        15.1. Market Player – Competition Matrix (By Tier and Size of companies)

        15.2. Market Share Analysis By Company (2022)

        15.3. Company Profiles

            15.3.1. Thermo Fisher Scientific, Inc.

                15.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.3.1.2. Material Portfolio

                15.3.1.3. Financial Overview

                15.3.1.4. SWOT Analysis

                15.3.1.5. Strategic Overview

            15.3.2. Genzyme Corporation (Sanofi)

                15.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.3.2.2. Material Portfolio

                15.3.2.3. Financial Overview

                15.3.2.4. SWOT Analysis

                15.3.2.5. Strategic Overview

            15.3.3. AbbVie, Inc.

                15.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.3.3.2. Material Portfolio

                15.3.3.3. Financial Overview

                15.3.3.4. SWOT Analysis

                15.3.3.5. Strategic Overview

            15.3.4. Sanofi

                15.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.3.4.2. Material Portfolio

                15.3.4.3. Financial Overview

                15.3.4.4. SWOT Analysis

                15.3.4.5. Strategic Overview

            15.3.5. Leadiant Biosciences

                15.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.3.5.2. Material Portfolio

                15.3.5.3. Financial Overview

                15.3.5.4. SWOT Analysis

                15.3.5.5. Strategic Overview

            15.3.6. Takeda Pharmaceutical Company Limited

                15.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.3.6.2. Material Portfolio

                15.3.6.3. Financial Overview

                15.3.6.4. SWOT Analysis

                15.3.6.5. Strategic Overview

            15.3.7. Amicus Therapeutics

                15.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.3.7.2. Material Portfolio

                15.3.7.3. Financial Overview

                15.3.7.4. SWOT Analysis

                15.3.7.5. Strategic Overview

            15.3.8. Bayer AG

                15.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.3.8.2. Material Portfolio

                15.3.8.3. Financial Overview

                15.3.8.4. SWOT Analysis

                15.3.8.5. Strategic Overview

            15.3.9. Bristol-Myers Squibb

                15.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.3.9.2. Material Portfolio

                15.3.9.3. Financial Overview

                15.3.9.4. SWOT Analysis

                15.3.9.5. Strategic Overview

            15.3.10. DAIICHI SANKYO COMPANY

                15.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.3.10.2. Material Portfolio

                15.3.10.3. Financial Overview

                15.3.10.4. SWOT Analysis

                15.3.10.5. Strategic Overview

            15.3.11. Abbott

                15.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.3.11.2. Material Portfolio

                15.3.11.3. Financial Overview

                15.3.11.4. SWOT Analysis

                15.3.11.5. Strategic Overview

            15.3.12. Sanofi

                15.3.12.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.3.12.2. Material Portfolio

                15.3.12.3. Financial Overview

                15.3.12.4. SWOT Analysis

                15.3.12.5. Strategic Overview

    List of Tables

    Table 01: Global Protein Therapeutics Market Value (US$ Mn) Forecast, by Application, 2017-2031

    Table 02: Global Protein Therapeutics Market Value (US$ Mn) Forecast, by Product, 2017-2031

    Table 03: Global Protein Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031

    Table 04: Global Protein Therapeutics Market Value (US$ Mn) Forecast, by Region, 2017-2031

    Table 05: North America Protein Therapeutics Market Value (US$ Mn) Forecast, by Application, 2017-2031

    Table 06: North America Protein Therapeutics Market Value (US$ Mn) Forecast, by Product, 2017-2031

    Table 07: North America Protein Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031

    Table 08: North America Protein Therapeutics Market Value (US$ Mn) Forecast, by Country, 2017-2031

    Table 09: Europe Protein Therapeutics Market Value (US$ Mn) Forecast, by Application, 2017-2031

    Table 10: Europe Protein Therapeutics Market Value (US$ Mn) Forecast, by Product, 2017-2031

    Table 11: Europe Protein Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031

    Table 12: Europe Protein Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031

    Table 13: Asia Pacific Protein Therapeutics Market Value (US$ Mn) Forecast, by Application, 2017-2031

    Table 14: Asia Pacific Protein Therapeutics Market Value (US$ Mn) Forecast, by Product, 2017-2031

    Table 15: Asia Pacific Protein Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031

    Table 16: Asia Pacific Protein Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031

    Table 17: Latin America Protein Therapeutics Market Value (US$ Mn) Forecast, by Application, 2017-2031

    Table 18: Latin America Protein Therapeutics Market Value (US$ Mn) Forecast, by Product, 2017-2031

    Table 19: Latin America Protein Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031

    Table 20: Latin America Protein Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031

    Table 21: Middle East & Africa Protein Therapeutics Market Value (US$ Mn) Forecast, by Application, 2017-2031

    Table 22: Middle East & Africa Protein Therapeutics Market Value (US$ Mn) Forecast, by Product, 2017-2031

    Table 23: Middle East & Africa Protein Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031

    Table 24: Middle East & Africa Protein Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031

    List of Figures

    Figure 01: Global Protein Therapeutics Market Size (US$ Mn) Forecast, 2017-2031

    Figure 02: Global Protein Therapeutics Market Value Share, by Product (2022)

    Figure 03: Global Protein Therapeutics Market Value Share, by Application (2022)

    Figure 04: Global Protein Therapeutics Market Value Share, by End-user (2022)

    Figure 05: Global Protein Therapeutics Market Value Share, by Region (2022)

    Figure 06: Global Protein Therapeutics Market Value Share, by Application, 2022 and 2031

    Figure 07: Global Protein Therapeutics Market Attractiveness Analysis, by Application, 2017-2031

    Figure 08: Global Protein Therapeutics Market Value Share, by Product, 2022 and 2031

    Figure 09: Global Protein Therapeutics Market Attractiveness Analysis, by Product, 2017-2031

    Figure 10: Global Protein Therapeutics Market Value Share, by Route of Administration, 2022 and 2031

    Figure 11: Global Protein Therapeutics Market Attractiveness Analysis, by Route of Administration, 2017-2031

    Figure 12: Global Protein Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2017-2031

    Figure 13: Global Protein Therapeutics Market Value Share, by Region, 2017-2031

    Figure 14: Global Protein Therapeutics Market Attractiveness Analysis, by Region, 2017-2031

    Figure 15: North America Protein Therapeutics Market Value Share, by Application, 2022 and 2031

    Figure 16: North America Protein Therapeutics Market Attractiveness Analysis, by Application, 2017-2031

    Figure 17: North America Protein Therapeutics Market Value Share, by Product, 2022 and 2031

    Figure 18: North America Protein Therapeutics Market Attractiveness Analysis, by Product, 2017-2031

    Figure 19: North America Protein Therapeutics Market Value Share, by Route of Administration, 2022 and 2031

    Figure 20: North America Protein Therapeutics Market Attractiveness Analysis, by Route of Administration, 2017-2031

    Figure 21: North America Protein Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2017-2031

    Figure 22: North America Protein Therapeutics Market Value Share, by Country, 2017-2031

    Figure 23: North America Protein Therapeutics Market Attractiveness Analysis, by Country, 2017-2031

    Figure 24: Europe Protein Therapeutics Market Value Share, by Application, 2022 and 2031

    Figure 25: Europe Protein Therapeutics Market Attractiveness Analysis, by Application, 2017-2031

    Figure 26 : Europe Protein Therapeutics Market Value Share, by Product, 2022 and 2031

    Figure 27: Europe Protein Therapeutics Market Attractiveness Analysis, by Product, 2017-2031

    Figure 28: Europe Protein Therapeutics Market Value Share, by Route of Administration, 2022 and 2031

    Figure 29: Europe Protein Therapeutics Market Attractiveness Analysis, by Route of Administration, 2017-2031

    Figure 30: Europe Protein Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2017-2031

    Figure 31: Europe Protein Therapeutics Market Value Share, by Country/Sub-region, 2017-2031

    Figure 32: Europe Protein Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2017-2031

    Figure 33: Asia Pacific Protein Therapeutics Market Value Share, by Application, 2022 and 2031

    Figure 34: Asia Pacific Protein Therapeutics Market Attractiveness Analysis, by Application, 2017-2031

    Figure 35: Asia Pacific Protein Therapeutics Market Value Share, by Product, 2022 and 2031

    Figure 36: Asia Pacific Protein Therapeutics Market Attractiveness Analysis, by Product, 2017-2031

    Figure 37: Asia Pacific Protein Therapeutics Market Value Share, by Route of Administration, 2022 and 2031

    Figure 38: Asia Pacific Protein Therapeutics Market Attractiveness Analysis, by Route of Administration, 2017-2031

    Figure 39: Asia Pacific Protein Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2017-2031

    Figure 40 : Asia Pacific Protein Therapeutics Market Value Share, by Country/Sub-region, 2017-2031

    Figure 41: Asia Pacific Protein Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2017-2031

    Figure 42: Latin America Protein Therapeutics Market Value Share, by Application, 2022 and 2031

    Figure 43: Latin America Protein Therapeutics Market Attractiveness Analysis, by Application, 2017-2031

    Figure 44: Latin America Protein Therapeutics Market Value Share, by Product, 2022 and 2031

    Figure 45: Latin America Protein Therapeutics Market Attractiveness Analysis, by Product, 2017-2031

    Figure 46: Latin America Protein Therapeutics Market Value Share, by Route of Administration, 2022 and 2031

    Figure 47: Latin America Protein Therapeutics Market Attractiveness Analysis, by Route of Administration, 2017-2031

    Figure 48: Latin America Protein Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2017-2031

    Figure 45: Latin America Protein Therapeutics Market Value Share, by Country/Sub-region, 2017-2031

    Figure 50: Latin America Protein Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2017-2031

    Figure 51: Middle East & Africa Protein Therapeutics Market Value Share, by Application, 2022 and 2031

    Figure 52: Middle East & Africa Protein Therapeutics Market Attractiveness Analysis, by Application, 2017-2031

    Figure 53: Middle East & Africa Protein Therapeutics Market Value Share, by Product, 2022 and 2031

    Figure 54: Middle East & Africa Protein Therapeutics Market Attractiveness Analysis, by Product, 2017-2031

    Figure 55: Middle East & Africa Protein Therapeutics Market Value Share, by Route of Administration, 2022 and 2031

    Figure 56: Middle East & Africa Protein Therapeutics Market Attractiveness Analysis, by Route of Administration, 2017-2031

    Figure 57: Middle East & Africa Protein Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2017-2031

    Figure 58: Middle East & Africa Protein Therapeutics Market Value Share, by Country/Sub-region, 2017-2031

    Figure 59: Middle East & Africa Protein Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2017-2031

Copyright © Transparency Market Research, Inc. All Rights reserved